Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine kinase in the B-cell receptor signaling pathway, is highly effective in several malignancies. Its ac...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Rogers, Kerry A., Andritsos, Leslie A., Wei, Lai, McLaughlin, Eric M., Ruppert, Amy S., Anghelina, Mirela, Blachly, James S., Call, Timothy, Chihara, Dai, Dauki, Anees, Guo, Ling, Ivy, S. Percy, James, Lacey R., Jones, Daniel, Kreitman, Robert J., Lozanski, Gerard, Lucas, David M., Ngankeu, Apollinaire, Phelps, Mitch, Ravandi, Farhad, Schiffer, Charles A., Carson, William E., Jones, Jeffrey A., Grever, Michael R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2021
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8225920/
https://ncbi.nlm.nih.gov/pubmed/33754642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020009688
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg